The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / RA Drug Tested & FDA Orders Drug-Interaction Studies for Kayexalate

RA Drug Tested & FDA Orders Drug-Interaction Studies for Kayexalate

November 11, 2015 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Barcitinib Promising in Phase 3 Trials
Baricitinib, a once-daily oral selective JAK1 and JAK2 inhibitor, has shown positive results in the Phase 3 RA-BEAM study.1,2 This is the fourth successful Phase 3 study of this agent for treating adults with moderate to severe active rheumatoid arthritis (RA). This study enrolled more than 1,300 adults with active RA despite use of methotrexate (MTX). The safety and efficacy of baricitinib was compared with placebo for 24 weeks or adalimumab for 52 weeks. Patients receiving MTX were randomized to receive either 4 mg barcitinib once daily, 40 mg subcutaneous adalimumab every other week or placebo.

You Might Also Like
  • U.S. FDA Declines to Approve Eli Lilly & Incyte Arthritis Drug
  • FDA Update: Biosiomilar to Adalimumab Receives FDA Approval
  • Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab
Also By This Author
  • New RA Therapy Promising in Clinical Trial

Baricitinib was proved superior to placebo in ACR20 response after 12 weeks of treatment. In addition, baricitinib-treated patients showed improvement in the secondary endpoint of DAS28-hsCRP disease activity score after 12 weeks of treatment compared with adalimumab-treated patients. Baricitinib was also superior to placebo in preventing progressive radiographic structural joint damage after 24 weeks of treatment. This result was maintained through 52 weeks of therapy. Serious adverse events were similar between baricitinib and placebo, but lower for adalimumab; and serious infection rates were comparable across all groups. Treatment-emergent side effects, including infections, were greater for active treatment groups compared with placebo-treated patients. Discontinuations due to adverse events were similar across all treatment groups.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Prior baricitinib Phase 3 studies included RA-BEACON,3 for patients who failed at least one tumor necrosis factor inhibitor and were taking stable doses of conventional disease-modifying anti-rheumatic drugs (DMARDs); RA-BUILD, for patients who had either failed or could not tolerate treatment with at least one conventional DMARD; and RA-BEGIN, which compared barcitinib with MTX monotherapy.4

FDA Orders Drug-Interaction Studies for Kayexelate
The U.S. Food and Drug Administration (FDA) is requiring the manufacturer of sodium polystyrene sulfonate (Kayexalate), which is used to manage hyperkalemia, to conduct drug-interaction studies to determine if it decreases the absorption of other orally administered medications.5 Current labeling describes sodium polystyrene sulfonate as having the potential to decrease absorption of lithium and thyroxine; however, more extensive drug-interaction studies have not been undertaken.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This new request stems from the FDA’s approval of a new potassium-lowering drug, patiromer (Valtassa), which bound to about half of medications tested, potentially diminishing their therapeutic effects. To decrease these effects, it’s recommended that patiromer be administered with at least six hours’ separation from other orally administered medications. Because patiromer binds agents, it’s now thought that sodium polystyrene sulfonate may also bind these agents—hence the recommendation for new studies.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates, Safety Tagged With: baricitinib, drug interaction, FDA, Food and Drug Administration, Kayexalate, sodium polystyrene sulfonate

You Might Also Like:
  • U.S. FDA Declines to Approve Eli Lilly & Incyte Arthritis Drug
  • FDA Update: Biosiomilar to Adalimumab Receives FDA Approval
  • Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab
  • FDA Update: FDA Delays Baricitinib Review & Removes Bupropion & Varenicline Warnings

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.